High court rules 'pay-for-delay' drug deals can face antitrust suits

In such deals, a drug maker agrees to pay a potential rival to delay selling a generic version. The decision may result in lower drug costs, advocates say.WASHINGTON — A brand-name drug maker can be sued for violating antitrust laws if it agrees to pay a potential competitor to delay selling a generic version, the Supreme Court ruled.

Read the whole article on LA Times - Health

More from LA Times - Health